Capricor Therapeutics Approves 2025 Equity Incentive Plan

The latest announcement is out from Capricor Therapeutics ( (CAPR) ).

Capricor Therapeutics, Inc. announced that its stockholders approved the 2025 Equity Incentive Plan during the 2025 Annual Meeting of Stockholders. This plan, previously approved by the Board of Directors, reserves 3,500,000 shares of common stock for equity-based awards to employees, non-employee directors, and consultants, with an automatic annual increase in shares authorized for issuance starting January 1, 2026, through January 1, 2035. This development is expected to enhance the company’s ability to attract and retain talent, thereby potentially impacting its operational capabilities and market positioning.

The most recent analyst rating on (CAPR) stock is a Buy with a $77.00 price target. To see the full list of analyst forecasts on Capricor Therapeutics stock, see the CAPR Stock Forecast page.

Spark’s Take on CAPR Stock

According to Spark, TipRanks’ AI Analyst, CAPR is a Neutral.

Capricor Therapeutics’ overall stock score is driven primarily by its significant regulatory milestone and strategic advancements, balanced against ongoing financial challenges and valuation risks. The company’s strong cash position and potential FDA approval are positive, but profitability and revenue generation remain key concerns.

To see Spark’s full report on CAPR stock, click here.

More about Capricor Therapeutics

Capricor Therapeutics, Inc. operates in the biotechnology industry, focusing on developing transformative cell and exosome-based therapeutics for the treatment and prevention of diseases. The company is known for its innovative approaches in regenerative medicine and has a market focus on addressing unmet medical needs.

Average Trading Volume: 2,124,919

Technical Sentiment Signal: Hold

Current Market Cap: $468.5M

For an in-depth examination of CAPR stock, go to TipRanks’ Stock Analysis page.